Results 261 to 270 of about 453,251 (315)
Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years
The current study found no evidence of cumulative increased safety risks with upadacitinib 15 or 30 mg for up to 6 years and over 9000 patient‐years of safety data in adults and adolescents. There were low rates of adjudicated major adverse cardiovascular events, adjudicated thromboembolic events and malignancies. Abstract Background Atopic dermatitis (
Christopher G. Bunick +13 more
wiley +1 more source
Achieving rapid control of itch in atopic dermatitis and prurigo nodularis may minimize symptomatology and disease burden. Analysis of clinical trials in atopic dermatitis and prurigo nodularis showed significantly more patients in nemolizumab versus placebo groups achieved a meaningful clinical response in itch within 48 h, and separation increased ...
Sonja Ständer +10 more
wiley +1 more source
Elastolytic Granulomatous Dermatoses: Toward a Unified Clinicopathological Concept
International Journal of Dermatology, EarlyView.
Rose Kathrin Caroline Moritz +2 more
wiley +1 more source
The SKINERGY study will investigate six immune‐mediated inflammatory skin diseases through a nationwide collaboration across all Dutch university medical centres. Involving 720 patients and 120 healthy volunteers, it is aimed at generating a high‐quality dataset to identify biomarkers that enable personalized treatment strategies and improved disease ...
N. G. Koster +68 more
wiley +1 more source
Mapping malignant T‐cell states and immune circuits in Sézary syndrome by single‐cell analysis
Peripheral blood single‐cell RNA‐seq from leukaemic CTCL defined three malignant T‐cell programmes: MTC CM, MTC Reg and MTC E/EM, each with distinct features and candidate vulnerabilities. For example, inferred immune circuits highlighted actionable IL‐10/JAK–TYK2–STAT3 signalling, KIR–MHC I inhibitory interactions and myeloid/B‐cell inflammatory and ...
Beth A. Childs +6 more
wiley +1 more source
Possible interesting link between Janus kinase 2 mutation and renovascular hypertension. [PDF]
Tamura K +4 more
europepmc +1 more source
Systematic review (51 studies; 547 patients) indicates dupilumab may unmask/worsen CTCL (mainly MF/SS). A French Delphi consensus recommends rigorous diagnostic workup, avoiding dupilumab in confirmed CTCL, discontinuing upon diagnosis, and favouring methotrexate or phototherapy.
Florent Amatore +8 more
wiley +1 more source
Systemic, Lifestyle and Environmental Modifying Factors in the Pathogenesis of Periodontitis
A variety of impacting factors in the pathogenesis of periodontitis exist, including systemic, lifestyle, and environmental factors. This review highlights the manifold mechanistic aspects of the link between the pathogenesis of periodontitis, addressing these numerous factors to supplement the long‐standing knowledge of the progression of the disease.
Groeger Sabine Elisabeth +5 more
wiley +1 more source
Inflammatory and Immunological Basis of Periodontal Diseases
The periodontal lesion emerges as an evolving immunological battlefield, where host–microbiome interactions, dysregulated immune responses, fragile resolution mechanisms, and inflammophilic dysbiosis converge to shift the balance from homeostasis to unrestrained tissue destruction.
Giacomo Baima +3 more
wiley +1 more source

